Long-term Follow-up of Participants Treated with Galapagos Chimeric Antigen Receptor (CAR) T-cell Therapies

Launched by GALAPAGOS NV · Oct 21, 2024

Keywords

ClinConnect Summary

This clinical trial is looking at the long-term effects of a treatment called Galapagos CAR T-cell therapy, which is used for certain blood cancers, known as hematological malignancies. The study aims to follow participants for up to 15 years after they received this therapy to see how safe and effective it is over time. Researchers want to check for any delayed side effects that could occur later and to understand the overall benefits and risks associated with the treatment. They will also monitor the persistence of the CAR T-cells in the body and ensure there are no unexpected risks linked to the therapy.

Anyone who has previously received Galapagos CAR T-cell therapy in a clinical trial or a specific access program is eligible to participate in this follow-up study. There are no specific exclusions, so if you’ve been treated, you can take part. Participants can expect regular check-ins and assessments over the 15 years to track their health and any changes related to the treatment. This is an important study that will help improve our understanding of how CAR T-cell therapy works in the long run.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • All participants who have been treated with a Galapagos CAR T-cell therapy in a clinical trial or Managed Access Program.
• Exclusion Criteria:
• • There are no exclusion criteria for this study